Research Reports | Market Assessment
September 2014

Entyvio (Wave 1) | LaunchTrends | US | 2014

Takeda’s Entyvio (vedolizumab) gained FDA approval in May 2014; the drug launched in the United States in June 2014. This report measures the impact of this novel agent on the moderate to severe ulcerative colitis (UC) and Crohn’s disease (CD) market following launch. The report evaluates physicians’ current awareness and familiarity with Entyvio, the advantages and disadvantages compared to currently available therapies, and the current and anticipated usage of the drug; as well as the drug’s promotional activity.

Login to access report
Back to all Market Assessment reports
Login to access report

launch Related Market Assessment Reports